Volociximab
As of the edition of 20 October 2026, Volociximab is an antibody: went quiet in 2012; acts on ITGA5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2012
- Kind
- Antibody
- Registered trials
- 10, 3 stopped early
- Disease areas
- Cancer; Hormones; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Volociximab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGA5 | Integrin alpha-5 | P08648 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 7 | 3 | 0 | 3 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PDL BioPharma | Lead sponsor of trials | 2004 to now |
| Abbott | Lead sponsor of trials | 2005 to now |
| AbbVie | Lead sponsor of trials | 2005 to now |
| Astellas | Lead sponsor of trials | 2008 to now |